Evidence map›Paper›PMID 37340337›Full record

ArticleBMC cancer2023

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.

Chi-Shin Tseng, Jui-Han Yang, Shi-Wei Huang, Yu-Jen Wang, Chung-Hsin Chen, Yeong-Shiau Pu, Jason Chia-Hsien Cheng, Chao-Yuan Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chi-Shin TsengGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine, No.1, Jen Ai road, Section 1, Taipei, Taiwan.
Jui-Han YangDepartment of Education, National Taiwan University Hospital, Taipei, Taiwan.
Shi-Wei HuangDepartment of Urology, National Taiwan University Hospital Yun-Lin Branch, Taipei, Taiwan.
Yu-Jen WangDivision of Radiation Oncology, Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Chung-Hsin ChenDepartment of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
Yeong-Shiau PuDepartment of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
Jason Chia-Hsien ChengGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine, No.1, Jen Ai road, Section 1, Taipei, Taiwan. jasoncheng@ntu.edu.tw.
Chao-Yuan HuangDepartment of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan. cyh540909@gmail.com.
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival.

methodsThis retrospective study obtained data from 202 patients who started abiraterone acetate or enzalutamide as first-line therapy for mCRPC between 2016 and 2021 from a single academic center. The primary endpoint was overall survival (OS) defined as the interval from the start of ARAT to death, loss to follow-up, or the end of the study period. The secondary endpoints were PSA decline, PSA nadir, and time to nadir (TTN) after ARATs. Kaplan-Meier survival analyses were applied for depicting OS. Cox proportional hazards model with inversed probability of treatment weighing-adjustment was used to validate the effect of patient, disease, and treatment response factors on OS.

resultsAmong 202 patients, 164 patients were treated with first-line ARATs alone and 38 patients received second-line chemotherapy. The median OS was not reached in patients with first-line ARATs alone and was 38.8 months in those with subsequent chemotherapy after failure from ARATs. OS was not different between the use of abiraterone and enzalutamide, though enzalutamide showed a higher rate of PSA decline ≧ 90% (56% versus 40%, p = 0.021) and longer TTN (5.5 versus 4.7 months, p = 0.019). Multivariable analysis showed that PSA nadir > 2 ng/mL [hazard ratio (HR) 7.04, p < 0.001] and TTN<7 months (HR 2.18, p = 0.012) were independently associated with shorter OS. Patients with both of these poor prognostic factors had worse OS compared to those who had 0-1 factors (HR 9.21, p < 0.001).

conclusionsPatients with mCRPC who received first-line ARATs had better survival if they had a PSA nadir[Formula: see text]2 ng/mL or a TTN[Formula: see text]7 months. Further study is needed to determine if an early switch in therapy for those in whom neither is achieved may impact OS.

Indexed as

Abiraterone AcetateProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsBenzamidesHumansMaleNitrilesPhenylthiohydantoinPrognosisProstate-Specific AntigenRetrospective StudiesTreatment OutcomeAbiraterone AcetateAndrogen AntagonistsBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific AntigenAbiraterone acetateAndrogensCastrationEnzalutamideProstatic neoplasms

Identifiers

PMID37340337
PMCPMC10283214
OpenAlexW4381430377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.